FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163778695> ?p ?o ?g. }

• W2163778695 abstract "Fibrates are a class of drugs characterised by mainly lowering high triglyceride, raising high-density lipoprotein (HDL) cholesterol, and lowering the small dense fraction of low-density lipoprotein (LDL) cholesterol. Their efficacy for secondary prevention of serious vascular events is unclear, and to date no systematic review focusing on secondary prevention has been undertaken.To assess the efficacy and safety of fibrates for the prevention of serious vascular events in people with previous cardiovascular disease (CVD), including coronary heart disease and stroke.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; Issue 9, 2014) on the Cochrane Library, MEDLINE (OVID, 1946 to October week 1 2014), EMBASE (OVID, 1980 to 2014 week 41), the China Biological Medicine Database (CBM) (1978 to 2014), the Chinese National Knowledge Infrastructure (CNKI) (1979 to 2014), Chinese Science and Technique Journals Database (VIP) (1989 to 2014). We also searched other resources, such as ongoing trials registers and databases of conference abstracts, to identify further published, unpublished, and ongoing studies.We included randomised controlled trials (RCTs) in which a fibrate (for example gemfibrozil, fenofibrate) was compared with placebo or no treatment. We excluded RCTs with only laboratory outcomes. We also excluded trials comparing two different fibrates without a placebo or no-treatment control.Two review authors independently selected trials for inclusion, assessed risk of bias, and extracted the data. We contacted authors of trials for missing data.We included 13 trials involving a total of 16,112 participants. Eleven trials recruited participants with history of coronary heart disease, two trials recruited participants with history of stroke, and one trial recruited participants with a mix of people with CVD. We judged overall risk of bias to be moderate. The meta-analysis (including all fibrate trials) showed evidence for a protective effect of fibrates primarily compared to placebo for the primary composite outcome of non-fatal stroke, non-fatal myocardial infarction (MI), and vascular death (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.83 to 0.94; participants = 16,064; studies = 12; I(2) = 45%, fixed effect). Fibrates were moderately effective for preventing MI occurrence (RR 0.86, 95% CI 0.80 to 0.93; participants = 13,942; studies = 10; I(2) = 24%, fixed effect). Fibrates were not effective against all-cause mortality (RR 0.98, 95% CI 0.91 to 1.06; participants = 13,653; studies = 10; I(2) = 23%), death from vascular causes (RR 0.95, 95% CI 0.86 to 1.05; participants = 13,653; studies = 10; I(2) = 11%, fixed effect), and stroke events (RR 1.03, 95% CI 0.91 to 1.16; participants = 11,719; studies = 6; I(2) = 11%, fixed effect). Excluding clofibrate trials, as the use of clofibrate was discontinued in 2012 due to safety concerns, the remaining class of fibrates were no longer effective in preventing the primary composite outcome (RR 0.90, 95% CI 0.79 to 1.03; participants = 10,320; studies = 7; I(2) = 50%, random effects). However, without clofibrate data, fibrates remained effective in preventing MI (RR 0.85, 95% CI 0.76 to 0.94; participants = 8304; studies = 6; I(2) = 47%, fixed effect). There was no increase in adverse events with fibrates compared to control. Subgroup analyses showed the benefit of fibrates on the primary composite outcome to be consistent irrespective of age, gender, and diabetes mellitus.Moderate evidence showed that the fibrate class can be effective in the secondary prevention of composite outcome of non-fatal stroke, non-fatal MI, and vascular death. However, this beneficial effect relies on the inclusion of clofibrate data, a drug that was discontinued in 2002 due to its unacceptably large adverse effects. Further trials of the use of fibrates in populations with previous stroke and also against a background treatment with statins (standard of care) are required." @default.
• W2163778695 created "2016-06-24" @default.
• W2163778695 creator A5015215059 @default.
• W2163778695 creator A5016099230 @default.
• W2163778695 creator A5017250084 @default.
• W2163778695 creator A5030769859 @default.
• W2163778695 creator A5032727769 @default.
• W2163778695 date "2015-10-25" @default.
• W2163778695 modified "2023-10-12" @default.
• W2163778695 title "Fibrates for secondary prevention of cardiovascular disease and stroke" @default.
• W2163778695 cites W1552709412 @default.
• W2163778695 cites W1816402885 @default.
• W2163778695 cites W1918267826 @default.
• W2163778695 cites W1968139680 @default.
• W2163778695 cites W1970516435 @default.
• W2163778695 cites W1975018096 @default.
• W2163778695 cites W1983498453 @default.
• W2163778695 cites W1984217297 @default.
• W2163778695 cites W2000197810 @default.
• W2163778695 cites W2005761359 @default.
• W2163778695 cites W2013837699 @default.
• W2163778695 cites W2029186389 @default.
• W2163778695 cites W2031113176 @default.
• W2163778695 cites W2035109451 @default.
• W2163778695 cites W2045337701 @default.
• W2163778695 cites W2045622064 @default.
• W2163778695 cites W2054851194 @default.
• W2163778695 cites W2060209571 @default.
• W2163778695 cites W2060237277 @default.
• W2163778695 cites W2068627985 @default.
• W2163778695 cites W2074184658 @default.
• W2163778695 cites W2078421357 @default.
• W2163778695 cites W2089016920 @default.
• W2163778695 cites W2093136584 @default.
• W2163778695 cites W2094626010 @default.
• W2163778695 cites W2094768566 @default.
• W2163778695 cites W2096210401 @default.
• W2163778695 cites W2106742165 @default.
• W2163778695 cites W2113652219 @default.
• W2163778695 cites W2115752151 @default.
• W2163778695 cites W2117092539 @default.
• W2163778695 cites W2120986848 @default.
• W2163778695 cites W2123604945 @default.
• W2163778695 cites W2124247204 @default.
• W2163778695 cites W2124481954 @default.
• W2163778695 cites W2125692663 @default.
• W2163778695 cites W2147176408 @default.
• W2163778695 cites W2152316341 @default.
• W2163778695 cites W2154634442 @default.
• W2163778695 cites W2156019168 @default.
• W2163778695 cites W2157823046 @default.
• W2163778695 cites W2163096122 @default.
• W2163778695 cites W2164324917 @default.
• W2163778695 cites W2167418276 @default.
• W2163778695 cites W2168231835 @default.
• W2163778695 cites W2182460401 @default.
• W2163778695 cites W2198678228 @default.
• W2163778695 cites W2328529137 @default.
• W2163778695 cites W2337032743 @default.
• W2163778695 cites W2341665659 @default.
• W2163778695 cites W2400712338 @default.
• W2163778695 cites W2406848229 @default.
• W2163778695 cites W2431527220 @default.
• W2163778695 cites W25884571 @default.
• W2163778695 cites W2725187802 @default.
• W2163778695 cites W2949679206 @default.
• W2163778695 cites W4205200114 @default.
• W2163778695 cites W4211109054 @default.
• W2163778695 cites W4211191293 @default.
• W2163778695 cites W4232807629 @default.
• W2163778695 cites W4238480239 @default.
• W2163778695 cites W4241589081 @default.
• W2163778695 cites W4244278365 @default.
• W2163778695 cites W4245557636 @default.
• W2163778695 cites W4255203399 @default.
• W2163778695 cites W4292172722 @default.
• W2163778695 cites W4296976561 @default.
• W2163778695 cites W4298856345 @default.
• W2163778695 cites W4376542714 @default.
• W2163778695 doi "https://doi.org/10.1002/14651858.cd009580.pub2" @default.
• W2163778695 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6494578" @default.
• W2163778695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26497361" @default.
• W2163778695 hasPublicationYear "2015" @default.
• W2163778695 type Work @default.
• W2163778695 sameAs 2163778695 @default.
• W2163778695 citedByCount "72" @default.
• W2163778695 countsByYear W21637786952014 @default.
• W2163778695 countsByYear W21637786952016 @default.
• W2163778695 countsByYear W21637786952017 @default.
• W2163778695 countsByYear W21637786952018 @default.
• W2163778695 countsByYear W21637786952019 @default.
• W2163778695 countsByYear W21637786952020 @default.
• W2163778695 countsByYear W21637786952021 @default.
• W2163778695 countsByYear W21637786952022 @default.
• W2163778695 countsByYear W21637786952023 @default.
• W2163778695 crossrefType "journal-article" @default.
• W2163778695 hasAuthorship W2163778695A5015215059 @default.
• W2163778695 hasAuthorship W2163778695A5016099230 @default.
• W2163778695 hasAuthorship W2163778695A5017250084 @default.
• W2163778695 hasAuthorship W2163778695A5030769859 @default.

• next